Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer

Clinical Cancer Research

Volumn 17, Issue 14, 2011, Pages 4799-4805

  Linden, Hannah M ^a   Kurland, Brenda F ^b   Peterson, Lanell M ^a   Schubert, Erin K ^a   Gralow, Julie R ^a   Specht, Jennifer M ^a   Ellis, Georgiana K ^a   Lawton, Thomas J ^a   Livingston, Robert B ^c   Petra, Philip H ^a   Link, Jeanne M ^a   Krohn, Kenneth A ^a   Mankoff, David A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROESTRADIOL F 18; FULVESTRANT; LETROZOLE; RADIOISOTOPE; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER LOCALIZATION; CANCER PATIENT; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR BINDING; SOFT TISSUE METASTASIS; TREATMENT RESPONSE; UTERUS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; UTERUS;

EID: 79960428275     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3321     Document Type: Article

References (28)

1. Iwase H. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer 2008;15:278-90.
2. Brodie AH, Jelovac D, Long B. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens. J Steroid Biochem Mol Biol 2003;86:283-8. (Pubitemid 37412566)
3. Bhatnagar AS, Brodie AM, Long BJ, Evans DB, Miller WR. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol 2001;76:199-202. (Pubitemid 32510682)
4. Chung CT, Carlson RW. The role of aromatase inhibitors in early breast cancer. Curr Treat Options Oncol 2003;4:133-40.
5. Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jørgensen LM, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001;67:111-6. (Pubitemid 32744491)
6. Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009;302:774-80.
7. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005;23:1616-22. (Pubitemid 46211414)
8. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura A, et al. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 2005;12 Suppl 1:S61-73.
9. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, et al. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol 2005;95:155-65. (Pubitemid 41137306)
10. Osipo C, Liu H, Meeke K, Jordan VC. The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death. Exp Biol Med (Maywood) 2004;229:722-31. (Pubitemid 39166476)
11. Mankoff DA. Molecular imaging to select cancer therapy and evaluate treatment response. Q J Nucl Med Mol Imaging 2009;53:181-92.
12. Peterson LM, Mankoff DA, Lawton T, Yagle K, Schubert EK, Stekhova S, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 2008;49:367-74. (Pubitemid 351355201)
13. Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988;169:45-8.
14. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ, et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;19:2797-803. (Pubitemid 32538187)
15. Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006;24:2793-9. (Pubitemid 46630578)
16. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA, et al. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26:51-6.
17. 18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32:1526-31.
18. 18F]-fluoroestradiol (FES) in patients with estrogen receptor positive (ER+) breast cancer. Nucl Med Biol. In press 2011.
19. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999;40:1771-7. (Pubitemid 29523568)
20. Lancaster H. Significance tests in discrete distributions. J Am Stat Assoc 1961;56:226-34.
21. Agresti A. Exact inference for categorical data: recent advances and continuing controversies. Stat Med 2001;20:2709-22. (Pubitemid 32834378)
22. Sabnis G, Schayowitz A, Goloubeva O, Macedo L, Brodie A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 2009;69:1416-28.
23. Howell A, Abram P. Clinical development of fulvestrant ("Faslodex"). Cancer Treat Rev 2005;31 Suppl 2:S3-9.
24. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605-13. (Pubitemid 41079798)
25. Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009;27:4530-5.
26. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28:4594-600.
27. Linden H, et al. Early assessment of response to aromatase inhibitor (AI) therapy. In: American Society of Clinical Oncology 2009 Annual Meeting; Orlando, FL: AACR; 2009. Abstract nr 11075.
28. Mankoff DA, Dehdashti F. Imaging tumor phenotype: 1 plus 1 is more than 2. J Nucl Med 2009;50:1567-9.